Search results
Results from the WOW.Com Content Network
Alongside these lifestyle changes, the use of antianginal drugs is a common approach. However, findings from randomized controlled trials reveal that the efficacy of various antianginal drugs is comparable, with none demonstrating a significant reduction in mortality or the risk of myocardial infarction (MI). Despite this, prevailing guidelines ...
Long-term randomized, controlled trials comparing trimetazidine against standard antianginal agents using clinically important outcomes would be justifiable. [32] A 2013 international multicentre retrospective cohort study has indeed shown that in patients with heart failure of different etiologies the addition of trimetazidine on conventional ...
Perhexiline (Pexsig) is a prophylactic antianginal agent used primarily in Australia and New Zealand. Perhexiline is thought to act by inhibiting mitochondrial carnitine palmitoyltransferase-1 . This shifts myocardial metabolism from fatty acid to glucose utilisation which results in increased ATP production for the same O 2 consumption and ...
Ivabradine is contraindicated in sick sinus syndrome. It should also not be used concomitantly with potent inhibitors of CYP3A4, including azole antifungals (such as ketoconazole), macrolide antibiotics, nefazodone and the antiretroviral drugs nelfinavir and ritonavir. [12] Use of ivabradine with verapamil or diltiazem is contraindicated. [13]
It falls under the umbrella of two other medication classes: analgesics (pain relievers) and antipyretics (fever reducers), says Dr. Anureet Walia, MD, a pain management specialist with UI Health ...
For premium support please call: 800-290-4726 more ways to reach us
It is not recommended in people with a slow heart rate or heart failure. [12] It is believed to cause problems for the fetus if used during pregnancy. [2] It is in the non–dihydropyridine calcium channel blocker family of medications. [9] Verapamil was approved for medical use in the United States in 1981.
As Americans are increasingly reaching for pharmaceutical solutions for depression—about one in eight U.S. adults takes antidepressants—scientists have been innovating novel treatments for it.